Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Blood|August 4, 2005
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trialsRosemary E Gale, Robert Hills, Panagiotis D Kottaridis, et al.
Blood|July 24, 2010
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD statusClaire L Green, Catherine M Evans, Robert K Hills, et al.
Blood|September 20, 2002
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitorsPanagiotis D Kottaridis, Rosemary E Gale, Stephen E Langabeer, et al.
British Journal of Haematology|July 9, 2002
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devicesMichael J Watts, Tim C P Somervaille, Stuart J Ings, et al.
Blood|October 25, 2007
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemiaRosemary E Gale, Claire Green, Christopher Allen, et al.
British Journal of Haematology|July 1, 2014
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathwaysKoremu Meja, Chloe Stengel, Rob Sellar, et al.
Blood|June 18, 2002
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs, Emma C Morris, Panos D Kottaridis, et al.
Blood|July 2, 2002
Paternal mosaicism proves the pathogenic nature of mutations in neutrophil elastase in severe congenital neutropeniaPhil J Ancliff, Rosemary E Gale, Michael J Watts, et al.
British Journal of Haematology|August 19, 2011
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapySally Moore, Karl Peggs, Kirsty Thomson, et al.
Leukemia & Lymphoma|August 20, 2013
ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratificationDima El-Sharkawi, Akbar Ali, Catherine M Evans, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Blood|August 4, 2005
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trialsRosemary E Gale, Robert Hills, Panagiotis D Kottaridis, et al.
Blood|July 24, 2010
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD statusClaire L Green, Catherine M Evans, Robert K Hills, et al.
Blood|September 20, 2002
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitorsPanagiotis D Kottaridis, Rosemary E Gale, Stephen E Langabeer, et al.
British Journal of Haematology|July 9, 2002
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devicesMichael J Watts, Tim C P Somervaille, Stuart J Ings, et al.
Blood|October 25, 2007
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemiaRosemary E Gale, Claire Green, Christopher Allen, et al.
British Journal of Haematology|July 1, 2014
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathwaysKoremu Meja, Chloe Stengel, Rob Sellar, et al.
Blood|June 18, 2002
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs, Emma C Morris, Panos D Kottaridis, et al.
Blood|July 2, 2002
Paternal mosaicism proves the pathogenic nature of mutations in neutrophil elastase in severe congenital neutropeniaPhil J Ancliff, Rosemary E Gale, Michael J Watts, et al.
British Journal of Haematology|August 19, 2011
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapySally Moore, Karl Peggs, Kirsty Thomson, et al.
Leukemia & Lymphoma|August 20, 2013
ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratificationDima El-Sharkawi, Akbar Ali, Catherine M Evans, et al.
Pageof 13